Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?
about
Subchronic administration of riparin III induces antidepressive-like effects and increases BDNF levels in the mouse hippocampus.Behavioral and neurochemical effects of alpha-lipoic Acid in the model of Parkinson's disease induced by unilateral stereotaxic injection of 6-ohda in rat.Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats.
P2860
Augmentation therapy with alpha-lipoic acid and desvenlafaxine: a future target for treatment of depression?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Augmentation therapy with alph ...... t for treatment of depression?
@en
Augmentation therapy with alph ...... t for treatment of depression?
@nl
type
label
Augmentation therapy with alph ...... t for treatment of depression?
@en
Augmentation therapy with alph ...... t for treatment of depression?
@nl
prefLabel
Augmentation therapy with alph ...... t for treatment of depression?
@en
Augmentation therapy with alph ...... t for treatment of depression?
@nl
P2093
P2860
P50
P1476
Augmentation therapy with alph ...... t for treatment of depression?
@en
P2093
Caren Nádia Soares de Sousa
Francisca Cléa Florenço Sousa
Jéssica Calheiros da Silva
Márcia Calheiros Chaves Silva
Naiara Coelho Ximenes
Paulo Victor Pontes Araújo
Suzyana Lima de Oliveira
P2860
P2888
P304
P356
10.1007/S00210-013-0867-Y
P577
2013-04-16T00:00:00Z